Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win

Novartis and Incyte's JAK inhibitor Jakafi has had a whirlwind few weeks as it rolls into a late-stage trial as a possible therapy for cytokine storm in COVID-19 patients. But Jakafi is also strengthening its hand in graft vs. host disease, where it scored its third approval earlier this year.